临床试验结果暗示 HCC 患者的新选择 2022 年 10 月 7 日

StephenW

临床试验结果暗示 HCC 患者的新选择
2022 年 10 月 7 日
乔丁·萨瓦

在接受 Targeted Oncology 采访时，医学博士 Ghassan K. Abou-Alfa 讨论了目前影响该领域的肝细胞癌领域的 3 篇最新摘要。
人物形象

在过去的 5 年中，肝细胞癌 (HCC) 领域已经出现了许多探索免疫肿瘤学 (IO) 疗法与 VEGF 抗体、酪氨酸激酶抑制剂 (TKI) 等相结合的试验。

目前，该领域存在超过 1 种标准治疗选择，包括一线治疗中阿特珠单抗 (Tecentriq) 加贝伐单抗 (Avastin) 或瑞戈非尼 (Stivarga) 的组合，以及卡瑞利珠单抗 (AiRuiK) 或纳武单抗 (AiRuiK)。 Opdivo）、易普利姆玛（Yervoy）和雷莫芦单抗（Cyramza）在二线治疗中。

尽管有很多选择，研究人员仍在继续为他们的患者寻找更好的结果。这包括单独研究新疗法并添加到标准护理方案中。

在 2022 年欧洲医学肿瘤学会 (ESMO) 大会上提交的 3 篇最新摘要中讨论了来自评估 HCC 新选择的试验的更新数据。

这些试验包括一线 tislelizumab 与索拉非尼的 3 期 RATIONALE-301 (NCT03412773) 研究、检验 PD-1 抑制剂 camrelizumab 与 rivoceranib 联合的 3 期研究 (NCT03764293) 以及 lenvatinib 的 3 期 LEAP-002 研究 (NCT03713593)加上派姆单抗（Keytruda）。

在接受 Targeted OncologyTM 采访时，Memorial Sloan Kettering Cancer Center 的医学肿瘤学家 Ghassan K. Abou-Alfa 医学博士讨论了目前影响该领域的 HCC 领域的 3 个最新摘要。

StephenW

Clinical Trial Results Allude to New Options for Patients With HCC
October 7, 2022
Jordyn Sava

In an interview with Targeted Oncology, Ghassan K. Abou-Alfa, MD, discussed 3 late breaking abstracts in the hepatocellular carcinoma space currently influencing the field.
figure image

The hepatocellular carcinoma (HCC) space has been presented with a number of trials exploring immune-oncology (IO) therapies combined with VEGF antibodies, tyrosine kinase inhibitors (TKIs), and more over the past 5 years.

Currently, more than 1 standard-of-care option exists in this space, including the combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) or regorafenib (Stivarga) in the first-line setting, and camrelizumab (AiRuiK), or nivolumab (Opdivo), ipilimumab (Yervoy), and ramucirumab (Cyramza) in the second-line setting.

Even though many options are available, investigators continue to look for better outcomes for their patients. This includes investigating novel therapies alone and adding onto the standard-of-care regimens.

Updated data from trials evaluating new options in HCC were discussed in 3 late breaking abstracts presented at the European Society for Medical Oncology (ESMO) Congress 2022.

These trials included the phase 3 RATIONALE-301 (NCT03412773) study of frontline tislelizumab vs sorafenib, a phase 3 study (NCT03764293) examining the PD-1 inhibitor camrelizumab combined with rivoceranib, and the phase 3 LEAP-002 study (NCT03713593) of lenvatinib plus pembrolizumab (Keytruda).

In an interview with Targeted OncologyTM, Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed 3 late breaking abstracts in the HCC space currently influencing the field.

StephenW

https://www.targetedonc.com/view ... r-patients-with-hcc